This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Lorvotuzumab mertansine
- DrugBank Accession Number
- DB12089
- Background
Lorvotuzumab mertansine has been used in trials studying the treatment of SCLC, Leukemia, Ovarian Cancer, Multiple Myeloma, and Merkel Cell Carcinoma, among others.
- Type
- Biotech
- Groups
- Investigational
- Biologic Classification
- Protein Based Therapies
Other protein based therapies - Protein Chemical Formula
- Not Available
- Protein Average Weight
- Not Available
- Sequences
- Not Available
- Synonyms
- Lorvotuzumab mertansine
- External IDs
- IMGN901
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbciximab The risk or severity of adverse effects can be increased when Abciximab is combined with Lorvotuzumab mertansine. Abemaciclib The metabolism of Abemaciclib can be decreased when combined with Lorvotuzumab mertansine. Acalabrutinib The metabolism of Acalabrutinib can be decreased when combined with Lorvotuzumab mertansine. Acenocoumarol The serum concentration of Acenocoumarol can be increased when it is combined with Lorvotuzumab mertansine. Acetyldigitoxin The serum concentration of Acetyldigitoxin can be increased when it is combined with Lorvotuzumab mertansine. Adalimumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Lorvotuzumab mertansine. Aducanumab The risk or severity of adverse effects can be increased when Lorvotuzumab mertansine is combined with Aducanumab. Albendazole The metabolism of Albendazole can be decreased when combined with Lorvotuzumab mertansine. Alectinib The metabolism of Alectinib can be decreased when combined with Lorvotuzumab mertansine. Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Lorvotuzumab mertansine. 
Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- Not Available
Categories
- Drug Categories
- Amino Acids, Peptides, and Proteins
- Anti-Bacterial Agents
- Antibodies
- Antibodies, Monoclonal
- Antibodies, Monoclonal, Humanized
- Antibody-drug Conjugates
- Antineoplastic Agents
- Antineoplastic Agents, Immunological
- Antineoplastic Agents, Phytogenic
- Blood Proteins
- Cytochrome P-450 CYP3A Inhibitors
- Cytochrome P-450 CYP3A4 Inhibitors
- Cytochrome P-450 CYP3A4 Inhibitors (strength unknown)
- Cytochrome P-450 Enzyme Inhibitors
- Globulins
- Immunoconjugates
- Immunoglobulins
- Immunologic Factors
- Immunoproteins
- Immunotoxins
- Lactams, Macrocyclic
- Lactones
- Macrolides
- Noxae
- Proteins
- Serum Globulins
- Toxic Actions
- Chemical TaxonomyProvided by Classyfire
- Description
- Not Available
- Kingdom
- Organic Compounds
- Super Class
- Organic Acids
- Class
- Carboxylic Acids and Derivatives
- Sub Class
- Amino Acids, Peptides, and Analogues
- Direct Parent
- Peptides
- Alternative Parents
- Not Available
- Substituents
- Not Available
- Molecular Framework
- Not Available
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 0IVD6ASY0W
- CAS number
- 1008106-64-6
References
- General References
- Not Available
- External Links
- PubChem Substance
- 347911280
- Wikipedia
- Lorvotuzumab_mertansine
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 2 Completed Treatment Leukemias 1 2 Completed Treatment Pleuropulmonary Blastoma / Recurrent Malignant Peripheral Nerve Sheath Tumor / Recurrent Neuroblastoma / Recurrent Rhabdomyosarcoma / Recurrent Synovial Sarcoma / Wilms' tumor 1 1 Completed Treatment Merkel Cell Carcinoma / Ovarian Cancer / Small Cell Lung Cancer (SCLC) 1 1 Completed Treatment Multiple Myeloma (MM) 2 1, 2 Terminated Treatment Small Cell Lung Cancer (SCLC) 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
Enzymes
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- No
- Actions
- Inhibitor
- General Function
- Vitamin d3 25-hydroxylase activity
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
- Gene Name
- CYP3A4
- Uniprot ID
- P08684
- Uniprot Name
- Cytochrome P450 3A4
- Molecular Weight
- 57342.67 Da
References
- Kuper JI, D'Aprile M: Drug-Drug interactions of clinical significance in the treatment of patients with Mycobacterium avium complex disease. Clin Pharmacokinet. 2000 Sep;39(3):203-14. doi: 10.2165/00003088-200039030-00003. [Article]
Drug created at October 20, 2016 21:19 / Updated at January 14, 2023 19:03